A new scientific statement calls for a shift in obesity management and treatment to focus on overall health improvements rather than just weight loss alone.
Commentary|Videos|January 10, 2024
Obesity Management: What Clinicians Need to Know in 2024
Author(s)Sydney Jennings
Angela Fitch, MD, president of the Obesity Medicine Association, details what to look forward to this year in terms of obesity management.
Advertisement
When asked in a recent interview what clinicians should look forward to in 2024 in terms of obesity medicine and obesity management, Angela Fitch, MD, president of the Obesity Medicine Association stated, "I hope that they would look forward to a day when comprehensive obesity care—we're talking about help with behavior changes, lifestyle intervention, dietitian coverage—is accessible to patients to help them accomplish their weight management goals."
In the conversation below, Dr Fitch discusses the importance of obesity care becoming a standard benefit on all insurance in 2024.
Dr Fitch is also the founder and chief medical officer at knownwell and the former co-director of the Massachusetts General Hospital Weight Center and faculty at Harvard Medical School.
Advertisement
Related to this article
Semaglutide brought 40.4% of children below the obesity BMI threshold, according to top-line results from the phase 3 STEP Young clinical trial.
US clinicians increasingly prescribe GLP-1 drugs to young children with obesity, although overall use remains limited and access disparities persist.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
New American Society of Hematology guidelines raise ferritin cutoffs to catch iron deficiency sooner, including pregnancy and inflammation, and add TSAT for clearer diagnosis.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
The FDA accepted Organon’s MIUDELLA supplemental application, but the proposed change, supporting data, and review timeline remain undisclosed.
Advertisement
Advertisement
Trending on Patient Care Online
1
ASH Raises Ferritin Thresholds for Diagnosing Iron Deficiency
2
Combating Prostate Cancer Misconceptions in Primary Care: An Expert Discussion
3
FDA Approves Finerenone for CKD Associated With Type 1 Diabetes
4
FDA Grants Priority Review to Zasocitinib for Plaque Psoriasis
5